Greenwich LifeSciences, Inc. (GLSI)
Automate Your Wheel Strategy on GLSI
With Tiblio's Option Bot, you can configure your own wheel strategy including GLSI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GLSI
- Rev/Share 0.0003
- Book/Share 0.1927
- PB 50.0357
- Debt/Equity 0.0
- CurrentRatio 2.6235
- ROIC -5.3029
- MktCap 128870412.0
- FreeCF/Share -0.5525
- PFCF -17.7348
- PE -8.0305
- Debt/Assets 0.0
- DivYield 0
- ROE -3.4114
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms.
Read More
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless …
Read More
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data.
Read More
About Greenwich LifeSciences, Inc. (GLSI)
- IPO Date 2020-09-25
- Website https://greenwichlifesciences.com
- Industry Biotechnology
- CEO Mr. Snehal S. Patel
- Employees 4